These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31688607)

  • 1. Prognostic Factors of Acinar Cell Carcinomas: A Study of 44 Patients.
    Egal A; Cros J; Svrcek M; Chiche L; Belleannee G; Poizat F; Jouffret L; Maire F; de Mestier L; Hammel P
    Pancreas; 2019; 48(10):1393-1396. PubMed ID: 31688607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen.
    Yoo C; Kim BJ; Kim KP; Lee JL; Kim TW; Ryoo BY; Chang HM
    Cancer Res Treat; 2017 Jul; 49(3):759-765. PubMed ID: 27857025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Analysis of Acinar Cell Carcinoma of the Pancreas: A Single-Center Experience of 45 Consecutive Cases.
    Zhou W; Han X; Fang Y; Han S; Cai Y; Kuang T; Lou W; Wang D
    Cancer Control; 2020; 27(1):1073274820969447. PubMed ID: 33121259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.
    Kruger S; Haas M; Burger PJ; Ormanns S; Modest DP; Westphalen CB; Kleespies A; Angele MK; Hartwig W; Bruns CJ; Kirchner T; Werner J; Heinemann V; Boeck S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2585-2591. PubMed ID: 27629876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.
    Takahashi H; Ikeda M; Shiba S; Imaoka H; Todaka A; Shioji K; Yane K; Kojima Y; Kobayashi S; Asagi A; Ozaka M; Takada R; Nagashio Y; Horiguchi S; Kasuga A; Suzuki E; Terashima T; Ueno M; Morizane C; Furuse J
    Pancreas; 2021 Jan; 50(1):77-82. PubMed ID: 33370026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review.
    Butturini G; Pisano M; Scarpa A; D'Onofrio M; Auriemma A; Bassi C
    Langenbecks Arch Surg; 2011 Mar; 396(3):363-9. PubMed ID: 20803029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.
    Holen KD; Klimstra DS; Hummer A; Gonen M; Conlon K; Brennan M; Saltz LB
    J Clin Oncol; 2002 Dec; 20(24):4673-8. PubMed ID: 12488412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma.
    Seo S; Yoo C; Kim KP; Ryoo BY; Chang HM; Hong SM; Lee JH; Song KB; Hwang DW; Kim KH; Hwang S; Kim SC
    J Dig Dis; 2017 Aug; 18(8):480-486. PubMed ID: 28671770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
    Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
    World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
    Uemura S; Maeda H; Tanioka N; Yamaguchi S; Munekage M; Kitagawa H; Namikawa T; Yamamoto S; Kohsaki T; Iguchi M; Uchida K; Hanazaki K
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1648. PubMed ID: 35668046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
    Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
    Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
    Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.